Stockreport

NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold [Yahoo! Finance]

Intellia Therapeutics, Inc.  (NTLA) 
Last intellia therapeutics, inc. earnings: 2/27 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.intelliatx.com/investor-overview
PDF study, MAGNITUDE-2, evaluating nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). NTLA shares gained ne [Read more]